UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
 Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

SLC47A2

Synonyms: FLJ31196, MATE2, MATE2-B, MATE2-K, MATE2K

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Kidney* Mean across all PMT Samples 5.030
Liver Mean across all PMT Samples    0.293
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
Acyclovir 4320 HEK293-MATE2K Tanihara, 2007
Amphetamine 16 HEK293-MATE2K Wagner, 2017
Cimetidine2,4 370 HEK293-MATE2K Masuda, 2006
Cimetidine2,4 120 HEK293-MATE2K Tanihara, 2007
Estrone sulfate 850 HEK293-MATE2K Tanihara, 2007
Ganciclovir 4280 HEK293-MATE2K Tanihara, 2007
Guanidine 4200 HEK293-MATE2K Tanihara, 2007
Hydrochlorothiazide 681 HEK293-MATE2K Yin, 2019
Ipratropium 95.7 HEK293-MATE2K Chen, 2017
Metformin1,3 1050 HEK293-MATE2K Masuda, 2006
Metformin1,3 1980 HEK293-MATE2K Tanihara, 2007
Methamphetamine 18 HEK293-MATE2K Wagner, 2017
N-methylpyridinium 93.5 HEK293-MATE2K Masuda, 2006
N-methylpyridinium 110 HEK293-MATE2K Tanihara, 2007
Procainamide 4100 HEK293-MATE2K Masuda, 2006
Procainamide 1580 HEK293-MATE2K Tanihara, 2007
Sulpiride 25.5 MDCK-MATE1 Li, 2017
Tetraethylammonium1 830 HEK293-MATE2K Masuda, 2006
Tetraethylammonium1 760 HEK293-MATE2K Tanihara, 2007
Topotecan 60 HEK293-MATE2K Tanihara, 2007
Trospium 8.2 HEK293-MATE2K Chen, 2017

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
1-methyl-4-phenylpyridinium (MPP+) 3.3 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Abemaciclib 0.75 Metformin1,3 HEK293-MATE2K Chappell, 2019
Agmatine 60.8 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Amantadine 89 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Amantadine 1167 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Amiloride 3.06 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Amphetamine 158 Metformin1,3 HEK293-MATE2K Wagner, 2017
Aripiprazole >500 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Atropine 52 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Bithionol 6.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Buspirone 46 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Butylscopolamine 38.2 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE2K Chen, 2017
Camostat 12.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Cetirizine 817.6 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Chlorhexidine 0.5 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Chloroquine 4 Ipratropium HEK293-MATE2K Chen, 2017
Chlorpheniramine 191.2 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Cimetidine2,4 39 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Kido, 2011
Cimetidine2,4 5.47 Metformin1,3 HEK293-MATE2K Lechner, 2016
Cimetidine2,4 7.3 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Cimetidine2,4 2.1 Tetraethylammonium1 HEK293-MATE2K Ito, 2012
Clonidine 54 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Cobicistat 3.2 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE2K Kikuchi, 2019
Dabigatran 25.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Dasatinib 0.8 Metformin1,3 HEK293-MATE2K Minematsu, 2011
Desipramine 283 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Dihydroergotamine 12.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Diltiazem 117 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Diphenhydramine 266.5 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Dipyridamole 74 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Kido, 2011
Disopyramide 100 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Kido, 2011
Disopyramide 291.6 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Domperidone 14.8 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
DX-619 0.1 Creatinine HEK293-MATE2K Imamura, 2011
Epinastine 29.8 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Erlotinib 3.45 Metformin1,3 HEK293-MATE2K Minematsu, 2011
Ethinyl estradiol 20.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Famotidine 6.28 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Famotidine 36.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Famotidine 9.7 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Gabexate 10.8 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Gefitinib 0.194 Metformin1,3 HEK293-MATE2K Minematsu, 2011
Granisetron 311 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Guanfacine 218 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Homatropine 128.3 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE2K Chen, 2017
Imatinib 0.35 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Imatinib 2.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Imipramine 100 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Kido, 2011
Imipramine 182.9 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Imiquimod 19.1 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Indinavir 7.8 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Indinavir >500 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Ipratropium 62.8 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE2K Chen, 2017
Irinotecan 7.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Irinotecan 78.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Ketoconazole 9.33 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Maraviroc 297 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Metamphetamine 84.3 Metformin1,3 HEK293-MATE2K Wagner, 2017
Metformin1,3 89.3 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Metformin1,3 6515.7 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Midodrine 87.1 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Mitoxantrone 0.53 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Mitoxantrone 0.83 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Moxifloxacin 7.6 Metformin1,3 HEK293-MATE2K Te, 2016
N-butylpyridinium chloride (NBuPy-Cl) 1.6 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Cheng, 2011
Naloxone 43.2 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Nialamide 236 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Nicotine 134 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Nifekalant 2.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Nifekalant 6.5 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Ondansetron 6.9 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Kido, 2011
Ondansetron 0.16 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Ondansetron 0.3 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Orphenadrine 100 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Kido, 2011
Pantoprazole 43.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Pantoprazole 500 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Pentamidine 2.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Pentamidine 10.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Phentolamine 5.3 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Pimozide >500 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Pramipexole 24.1 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Prazosin 38.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Procainamide 19.1 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Procainamide 178.1 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Proguanil 1.39 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Propranolol 7.71 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Pyrimethamine2 0.059 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Pyrimethamine2 0.01 Ipratropium HEK293-MATE2K Chen, 2017
Quinidine 1.47 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Quinidine 23.1 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Quinine 6.4 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Ranitidine 10 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Ranitidine 25 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Rimantadine 288 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Risperidone 291 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Ritonavir 4.4 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Ritonavir 23.7 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Scopolamine 272 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Sunitinib 0.86 Metformin1,3 HEK293-MATE2K Minematsu, 2011
Tacrine 1.1 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Tacrine 100 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Kido, 2011
Talipexole 119.5 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Topotecan 8.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Tramadol 74 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Trimethoprim4 2.61 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Trospium 5.1 1-methyl-4-phenylpyridinium (MPP+) HEK293-MATE2K Chen, 2017
Tubocurarine 55.5 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Vecuronium bromide 25.2 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013
Verapamil 37.9 1-methyl-4-phenylpyridinium (MPP+) CHO-MATE2K Astorga, 2012
Verapamil 32.1 Tetraethylammonium1 HEK293-MATE2 Tsuda, 2009
Zafirlukast 7.6 4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+) HEK293-MATE2K Wittwer, 2013

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

DDI Implicated Transporter Interacting Drug Affected Drug AUC Cmax CLR CL/F t1/2 Effect on PD Reference More Details
Clinical PK Impact(fold change)
1 OCT2/MATEs Abemaciclib Metformin1,3 1.37 1.22 0.55 ND NS yes Chappell, 2019 DDI 1
2 OCTs/MATE2K Cefiderocol Metformin1,3 1.05 1.09 ND NR 0.88 ND Katsube, 2018 DDI 2
3 OCTs/MATEs Cetirizine Pilsicainide 1.4 NS ND ND ND ND Tsuruoka, 2006 DDI 3
4 OCTs/MATEs Cimetidine2,4 Cephalexin NS NS 0.8 0.8 NS ND van, 1986 DDI 4
5 OCTs/MATEs Cimetidine2,4 Dofetilide 1.5 1.3 0.7 0.7 1.3 yes Abel, 2000 DDI 5
6 OCTs/MATEs Cimetidine2,4 Metformin1,3 1.5 1.7 0.7 ND ND ND Somogyi, 1987 DDI 6
7 OCTs/MATEs Cimetidine2,4 Pilsicainide 1.3 NS 0.7 0.7 1.2 ND Shiga, 2000 DDI 7
8 OCTs/MATEs Cimetidine2,4 Pindolol (S-enantiomer) 1.4 1.3 0.7 ND NS ND Somogyi, 1992 DDI 8
9 OCTs/MATEs Cimetidine2,4 Procainamide 1.4 NS 0.6 ND 1.3 ND Somogyi, 1983 DDI 9
10 OCTs/MATEs Cimetidine2,4 Ranitidine 1.3 NS 0.7 ND 1.3 ND van, 1986 DDI 10
11 OCTs/MATEs Cimetidine2,4 Varenicline 1.3 ND 0.8 0.8 ND ND Feng, 2008 DDI 11
12 OCTs/MATEs Isavuconazole4 Metformin1,3 1.52 1.22 ND 0.66 1.14 ND Yamazaki, 2017 DDI 12
13 OCTs/MATEs Plazomicin Metformin1,3 1.04 1.1 0.99 0.97 0.92 Choi, 2019 DDI 13
14 MATEs Pyrimethamine2 Metformin1,3 1.4 1.4 0.6 ND ND ND Kusuhara, 2011 DDI 14
15 OCTs/MATEs Ranitidine Trospium (IV) 1.06 1.10 0.87 1.1 1.00 No Abebe, 2020 DDI 15
16 OCTs/MATEs Ranitidine Trospium (oral) 0.87 0.92 0.99 NR 0.98 No Abebe, 2020 DDI 16
17 OCTs/MATEs Test cocktail 1: digoxin, furosemide, metformin, and rosuvastatin Metformin1,3 0.99 1.1 Stopfer, 2016 DDI 17
18 OCTs/MATEs Test cocktail 3: digoxin, metformin, rosuvastatin, and increased furosemide Metformin1,3 1.03 1.03 Stopfer, 2016 DDI 18
19 OCT1/MATEs Verapamil Metformin1,3 1.07 1.09 0.98 NR 0.80 Yes Cho, 2014 DDI 19

The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PK = pharmacokinetic
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Contact us | Glossary

Blue banner